A big step towards ultrafast cell line development
Harvard’s Wyss Institute joins forces with LAN partner Cytosurge to improve CRISPR-based multiplexed gene editing. The collaboration focuses on developing multiplexed gene editing approaches using single-cell nano-manipulation technology that maintains cell viability and fitness.
(BOSTON & ZURICH) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cytosurge AG, a company manufacturing unique high-precision nanotechnology instruments, announced that they will collaboratively investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity. This capability could become instrumental in driving forward diverse large-scale efforts such as the engineering of cell lines for pharmaceutical, clinical and biotechnological applications,transplantable immune-compatible pig organs, and the resurrection of extinct species.
